GlassScriptPhysician profile
Michael F Esposito
NPI 1043521198
$776,575.50
in general payments reported to CMS, 2019-2025
52 companies · $76K in 2025
The $76K reported for 2025 was more than what 99% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $87K · 2021: $196K · 2022: $124K · 2023: $111K · 2024: $75K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $184K · Consulting Fee: $43K · Food and Beverage: $19K · Travel and Lodging: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $878 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $183,907.50 |
| Consulting Fee | $43,262.46 |
| Food and Beverage | $18,509.52 |
| Travel and Lodging | $15,996.72 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $877.50 |
| Education | $208.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $534,712.96 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Therapies |
| Abbott Laboratories | $101,857.16 | 2019-2025 | Proclaim, Eterna |
| Nevro Corp. | $36,219.88 | 2019-2024 | Senza |
| Vertiflex, INC. | $28,971.34 | 2019 | |
| Stimwave Technologies Incorporated | $16,639.27 | 2019-2022 | |
| Curonix LLC | $14,749.81 | 2022-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Orthofundamentals, LLC | $9,638.96 | 2023-2024 | |
| Medtronic, INC. | $9,018.61 | 2021-2025 | Kyphon Express II Kyphopak Tray |
| Medtronic USA, INC. | $7,538.95 | 2019-2020 | |
| Vertos Medical, INC. | $3,715.22 | 2019-2022 | |
| Tersera Therapeutics LLC | $3,550.34 | 2019-2023 | Prialt |
| Spinal Simplicity, LLC | $3,129.15 | 2021-2025 | Ha Minuteman G3-R |
| Foundation Fusion Solutions, LLC | $1,810.12 | 2019-2024 | |
| Relievant Medsystems, INC. | $985.05 | 2021-2023 | Intracept |
| Painteq LLC | $979.97 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$662,748.86 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Esposito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.